The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies

Area of Science:

• Immunotherapy
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors like PD-(L)1 have transformed cancer treatment.
• Adding CTLA-4 inhibitors improves efficacy but increases immune-related adverse events.
• There is a need for novel immune checkpoints to enhance therapy with reduced toxicity.

Purpose of the Study:

• To review the mechanism of lymphocyte-activation gene 3 (LAG-3) as an immune checkpoint.
• To discuss the rationale for targeting LAG-3 in anticancer therapy.
• To summarize current data on LAG-3 inhibitors in melanoma and other solid tumors.

Main Methods:

• Literature review of preclinical and clinical studies on LAG-3 inhibitors.
• Analysis of the mechanism of action for LAG-3 and its role in T-cell regulation.
• Review of clinical trial data for LAG-3 targeting agents, including combination therapies.

Main Results:

• Lymphocyte-activation gene 3 (LAG-3) inhibits T-cell function by modulating the T-cell receptor pathway.
• The combination of relatlimab (a LAG-3 inhibitor) and nivolumab (a PD-1 inhibitor) demonstrates superior efficacy in advanced melanoma compared to PD-1 inhibition alone.
• This combination shows a potentially more favorable toxicity profile than ipilimumab (a CTLA-4 inhibitor) plus nivolumab.

Conclusions:

• LAG-3 is a promising immune checkpoint target for enhancing anticancer immunotherapy.
• Combination therapy with LAG-3 and PD-1 inhibitors, such as nivolumab plus relatlimab, offers a new treatment strategy for melanoma.
• Further investigation into LAG-3 inhibitors and novel targeting mechanisms is warranted for various solid tumors.